Impact of Metformin on Leptin Transport in Cerebrospinal Fluid of Obese Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-03

Study Completion Date

2024-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obesity, a major health problem, is gradually transforming into a global epidemic. The current obesity treatment with long term efficacy is the bariatric surgery, however, the operative risk of this procedure is high and the post-operative iotrogeny may be important. Obesity is most often associated to the feeding behavior which depends on hypothalamic integration of peripheral signals such as leptin and glucose. High levels of circulating leptin are detected in obese patients. These elevated leptin levels fail to reduce appetite or increase energy expenditure. The mechanism underlying this non-integration of peripheral signals remains to be identified. The ratio of leptin levels in the cereprospinal fluid (CSF) and in the periphery is drastically decreased in obese patients when compared to lean individuals, therefore a defective transport of circulating leptin into the brain via the CSF is maybe linked to obesity.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Metformin and Core Temperature in Obese and Lean Males

NCT02783053

Obesity

COMPLETED NA

Effect of Metformin on Exercise-induced Lipolysis

NCT03189732

Diabetes Mellitus, Type 2

COMPLETED NA

The Effects of Calorie Restriction With or Without Metformin on Weight and Insulin Resistance

NCT00134290

Body Weight Insulin Resistance

COMPLETED PHASE4

Metabolic Effects of a Caloric Restriction High/Low Glycemic Index Diet Plus Metformin in Overweight/Obese Subjects

NCT01460797

Obesity

COMPLETED NA

Effect of the Glycemic Index of Diet on Metabolic and Reproductive Parameters in Overweight and Obese Infertile Women

NCT02416960

Female Infertility Obesity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We hypothesize that the alteration of leptin transport into the CSF of obese patients could be modulated by drugs such as metformin which is widely used worldwide to treat diabetes. This study is monocentric, prospective, one-arm type and interventional. The main objective isto evaluate the impact of metformin on the transport of leptin into the CSF of obese patients.

We propose to show a variation of CSF leptin / serum leptin before and after metformin treatment and study its association with changes in hypothalamic metabolic activity, cognitive and appetite-related behaviors and ratio of other metabolic signals. This would support the hypothesis of modulation of resistance to peripheral leptin by metformin and thus uncover a new indication for metformin treatment towards the management of obesity.

For this purpose, volunteers will be subjected to blood sampling via venipuncture, CSF collection via lumbar puncture, MRI assessments and questionnaires (cognitive tests, food survey and feeding behavior) before and after a 3-month metformin treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity Without Type 2 Diabetes, With BMI>30

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Obese patients

Patients with body mass index \>30

Group Type EXPERIMENTAL

Metformin Oral Tablet

Intervention Type DRUG

Day 1 to day 3: 500 mg/day Day 4 to day 6: 500 mg/twice a day Day 7 to day 9: 500 mg three times a day Day 10 until next lumbar puncture : 850 mg three times a day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Metformin Oral Tablet

Day 1 to day 3: 500 mg/day Day 4 to day 6: 500 mg/twice a day Day 7 to day 9: 500 mg three times a day Day 10 until next lumbar puncture : 850 mg three times a day

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults between 18 and 40 years old
* Body mass index \>30
* For childbearing age women: use of an effective contraceptive method for the duration of the study
* Patients willing to participate in the study and who have signed the informed consent form
* Patients with health insurance

Exclusion Criteria

* Genetic obesity
* Type 2 diabetes defined by 2 fasting blood glucose \>1,26g/L or blood glucose \>2 g/L at 120 min of oral glucose tolerance test with 75 g of glucose
* Patients already treated with metformin
* Type 1 diabetes
* Active neoplastic pathology, diagnosed \< 5 years, or in treatment
* Neurological pathology (demyelinating, tumor, vascular)
* Adipose tissue pathology (lipodystrophy)
* History of bariatric surgery
* Contraindication to metformin
* Lumbar puncture contraindication
* MRI contraindication
* Person unable to consent, or benefiting from a legal protection regime (guardianship/curatorship/guardianship of justice)
* Pregnant or breastfeeding woman
* Contra-indication to impedance measurement
* Contraindication to indirect calorimetry: claustrophobia
* Taking a psychotropic drug

Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No